Alumni of UC Berkeley (Graduate)
Alumni of UC San Francisco (Professional)
HandL is developing a drug-free, portable, non-invasive neuromodulation device for treating migraine by electrically stimulating the peripheral nerves of the palm. The Company has demonstrated safety and efficacy in a pilot study at UCSF. The Company is also conducting studies using the technology for the treatment of other neurological disorders. Migraine is a highly prevalent and incapacitating neurological disorder. Episodic Migraine (EM) affects 12% of the population, and 18% of women. Specifically, healthcare and lost productivity costs associated with migraine are estimated to be as high as $36 billion annually in the United States. HandL offers an easy-to-use and discreet therapy to treat migraines and improve the quality of life. There is a prime commercial opportunity to capture the >$6B global headache market.
Primary Industry Sector: Medical Devices
Funding Status: Seed